Cite
A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.
MLA
Lickliter, Jason, et al. “A Phase I Randomized, Double‐blinded, Placebo‐controlled Study Assessing the Safety and Pharmacokinetics of RIPK1 Inhibitor GFH312 in Healthy Subjects.” CTS: Clinical & Translational Science, vol. 16, no. 9, Sept. 2023, pp. 1691–703. EBSCOhost, https://doi.org/10.1111/cts.13580.
APA
Lickliter, J., Wang, S., Zhang, W., Zhu, H., Wang, J., Zhao, C., Shen, H., & Wang, Y. (2023). A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects. CTS: Clinical & Translational Science, 16(9), 1691–1703. https://doi.org/10.1111/cts.13580
Chicago
Lickliter, Jason, Shuang Wang, Wenxin Zhang, Huaqiang Zhu, Jing Wang, Congqiao Zhao, Haige Shen, and Yu Wang. 2023. “A Phase I Randomized, Double‐blinded, Placebo‐controlled Study Assessing the Safety and Pharmacokinetics of RIPK1 Inhibitor GFH312 in Healthy Subjects.” CTS: Clinical & Translational Science 16 (9): 1691–1703. doi:10.1111/cts.13580.